Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 10/20 | 0.80 |
| ▸ | GRIN1 | Q05586 | 9/20 | 0.80 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.80 |
| ▸ | GRM5 | P41594 | 1/20 | 0.80 |
| ▸ | HTR1A | P08908 | 1/20 | 0.50 |
| ▸ | DRD2 | P14416 | 1/20 | 0.50 |
| ▸ | HTR2A | P28223 | 1/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.50 |
| ▸ | HTR7 | P34969 | 1/20 | 0.50 |
| ▸ | HRH1 | P35367 | 1/20 | 0.50 |
| ▸ | DRD3 | P35462 | 1/20 | 0.50 |
| ▸ | HTR2B | P41595 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3424183 | 0.89 | GRIN2B (1.00) | GRIN2BGRIN1SIGMAR1GRM5 | |
| SCHEMBL22015074 | 0.86 | GRIN2B (0.65) | GRIN2BGRIN1SIGMAR1GRM5 | |
| SCHEMBL23178364 | 0.85 | GRIN2B (0.81) | GRIN2BGRIN1SIGMAR1GRM5 | |
| SCHEMBL22015075 | 0.83 | GRIN2B (0.73) | GRIN2BGRIN1SIGMAR1GRM5 | |
| SCHEMBL3398496 | 0.82 | GRIN2B (1.00) | GRIN2BGRIN1SIGMAR1GRM5HTR1A | |
| SCHEMBL7888901 | 0.79 | GRIN2B (0.78) | GRIN2BGRIN1SIGMAR1GRM5 | |
| SCHEMBL23178360 | 0.78 | GRIN2B (0.88) | GRIN2BGRIN1SIGMAR1GRM5 | |
| SCHEMBL19216355 | 0.77 | GRIN2B (0.78) | GRIN2BGRIN1SIGMAR1GRM5 | |
| SCHEMBL19213968 | 0.76 | GRIN2B (0.78) | GRIN2BGRIN1SIGMAR1GRM5 | |
| SCHEMBL23036037 | 0.75 | GRIN2B (0.83) | GRIN2BGRIN1SIGMAR1GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220118118-A1 | BENZAZEPIN-L,7-DIOL-DERIVED RADIOLABELED LIGANDS WITH HIGH IN VIVO NMDA SPECIFICITY | ETH ZURICH (CH) | 2022-04-21 | — | — | US | disclosed |
| WO-2020099537-A1 | BENZAZEPIN-L,7-DIOL-DERIVED RADIOLABELED LIGANDS WITH HIGH IN VIVO NMDA SPECIFICITY | ETH ZURICH (CH) | 2020-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220118118-A1 | BENZAZEPIN-L,7-DIOL-DERIVED RADIOLABELED LIGANDS WITH HIGH IN VIVO NMDA SPECIFICITY | GRIN1, GRIN2D, GRIN3B | GRIN2B 4/4885GRIN1 1/4885SIGMAR1 457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.